GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointment of Walter M. Capone as Chief Business Officer. In his role as CBO, Mr. Capone will lead the expansion of pharmaceutical and biotech drug development collaborations involving GeneCentric’s Cancer Subtyping Platform (CSP™), and will oversee the company’s commercial strategy and growth.
“We are excited to have Walter join our strong leadership team,” said Chief Executive Officer Dr. Myla Lai-Goldman. “His expertise in drug development and commercialization will enable GeneCentric Therapeutics to actively expand its pharmaceutical and biotech company collaborations to advance therapeutic breakthroughs.”
Robin Toft, President and CEO of Toft Group said: “GeneCentric is a forward-thinking organization with an incredibly passionate leadership team. Walter will add great value to the organization, and will be a strong contributor to the continued growth of the company.”
Mr. Capone most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his accomplishments. Prior to joining the MMRF, Mr. Capone had over 20 years of pharma/biotech leadership experience in the United States and internationally in the areas of oncology, immunology and infectious disease drug development and commercialization at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, and Lederle. He received his MBA from Columbia University Business School and BA from Brown University.
About Toft Group Executive Search
Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.
GeneCentric Therapeutics, Inc. is a privately-held precision medicine company that is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By defining subtypes of cancer, CSP™ can enable drug developers to better predict drug response and determine why drugs fail in late stage clinical trials. GeneCentric creates and applies technologies focused on enhancing, accelerating and de-risking the costly drug development process to enable its industry partners to advance therapies which obtain the best possible patient treatment outcomes. GeneCentric was founded in 2011 and is based in Durham, NC. In addition to Bristol-Myers Squibb, its investors include Hatteras Venture Partners and Laboratory Corporation of America.